Aardvark Therapeutics (NASDAQ:AARD) Issues Quarterly Earnings Results, Hits Expectations

Aardvark Therapeutics (NASDAQ:AARD) posted its quarterly earnings data on Monday. The company reported ($0.81) EPS for the quarter, meeting analysts’ consensus estimates of ($0.81), FiscalAI reports.

Aardvark Therapeutics Stock Down 7.4%

Shares of NASDAQ:AARD opened at $3.77 on Wednesday. The company has a market cap of $82.08 million and a PE ratio of -1.29. Aardvark Therapeutics has a fifty-two week low of $3.55 and a fifty-two week high of $17.94. The firm has a 50-day simple moving average of $10.59 and a 200 day simple moving average of $11.68.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on AARD shares. Stifel Nicolaus reissued a “hold” rating and issued a $6.00 target price (down from $24.00) on shares of Aardvark Therapeutics in a research report on Monday, March 2nd. HC Wainwright reiterated a “neutral” rating on shares of Aardvark Therapeutics in a research note on Monday, March 2nd. BTIG Research reissued a “buy” rating and issued a $9.00 price objective on shares of Aardvark Therapeutics in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research note on Monday, December 29th. Finally, William Blair started coverage on Aardvark Therapeutics in a report on Friday, December 12th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.09.

Hedge Funds Weigh In On Aardvark Therapeutics

Institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Aardvark Therapeutics during the 2nd quarter worth approximately $42,000. China Universal Asset Management Co. Ltd. acquired a new position in Aardvark Therapeutics during the 4th quarter valued at approximately $47,000. Persistent Asset Partners Ltd bought a new position in Aardvark Therapeutics during the 4th quarter worth $56,000. New York State Common Retirement Fund bought a new position in Aardvark Therapeutics during the 2nd quarter worth $99,000. Finally, MetLife Investment Management LLC acquired a new stake in Aardvark Therapeutics in the fourth quarter worth $102,000.

Aardvark Therapeutics News Summary

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed a “buy” rating and set a $9.00 price target, signaling analyst conviction in longer-term upside despite recent setbacks. BTIG Buy Rating
• Neutral Sentiment: The company reported Q4 and full‑year 2025 results and posted ($0.81) EPS, which matched analyst estimates — the quarter itself was not a surprise and does not explain the sharp intraday move. Earnings Press Release
• Neutral Sentiment: Short-interest reports in the data feed are inconsistent (some entries show a March 13 decline to ~1.38M shares or ~6.4% of float with a ~1.7 days-to-cover, while other entries display erroneous zeros). The mixed/erroneous data make short-interest impact unclear for today’s move.
• Negative Sentiment: The company announced a voluntary pause of its Phase 3 HERO and OLE trials for ARD‑101 (hyperphagia in Prader‑Willi syndrome) and broader pauses related to its obesity candidate, which effectively puts core programs on hold — a material setback for a development‑stage biotech and the primary driver of investor concern. Company Update (trial pause)
• Negative Sentiment: Independent reporting highlights safety and cardiac concerns related to the obesity program and states the company has halted trials, increasing clinical and regulatory uncertainty and raising the chance of longer‑term pipeline delays. BioSpace article FierceBiotech article
• Negative Sentiment: Pomerantz LLP has launched an investor investigation into Aardvark, which adds potential litigation risk and can amplify downward pressure on the stock while uncertainty persists. Pomerantz Investigation

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.